BenevolentAI accelerates drug discovery by leveraging its proprietary AI platform, the Benevolent Platform™, to generate novel insights and increase the probability of clinical success.
Business Specialistbenevolent.comTracked since 2026-08-211 discovery source
10.7KBacklinks
2KReferring domains
31Domain authority
+0.1%Referring domains · 90 days
Authority & distribution
How strong is BenevolentAI’s web footprint?
Backlinks measure accumulated distribution; referring domains show how broadly that authority is spread. Both are observable on the open web, so both are published for every product here.
Backlinks
10.7KCurrent snapshot
Referring domains
2KCurrent snapshot
Authority
31Domain authority · category median 22
90-day move
+0.1%Referring domains, last 90 days
At 31, BenevolentAI sits above the 22 median for its category.
Trajectory · Pro
The counts above are the latest of 370 daily observations. The curve through them is on the full profile.
Traffic makes more sense when you can connect it to the actual product promise.
“BenevolentAI”
BenevolentAI accelerates drug discovery by leveraging its proprietary AI platform, the Benevolent Platform™, to generate novel insights and increase the probability of clinical success.
Business SpecialistSeen 2026-08-21 → 2026-08-21Coverage tier C
What we have measured
4 of 8 signal groups are available for this product: identity, authority and backlinks, AI referrals, search demand.
Not measured for this domain: traffic and engagement, audience demographics, country distribution, acquisition mix. Those sections are left out of the page rather than filled with estimates.
Canonical website: https://www.benevolent.com
Observed across 1 discovery source.
Research questions
What the evidence answers about BenevolentAI.
Every answer is tied to a source we collected, and the questions with no evidence behind them are left unanswered rather than guessed.
What does BenevolentAI do?
BenevolentAI accelerates drug discovery by leveraging its proprietary AI platform to generate novel insights and increase the probability of clinical success. Its technology builds on a decade of investment in a knowledge graph and proprietary ontologies to support scientists and executives.
What problem does BenevolentAI solve?
BenevolentAI solves the problem of accelerating complex drug discovery and development processes in biopharma. It targets the complex decisions that drive R&D, aiming to increase the probability of clinical success.
What does BenevolentAI offer?
BenevolentAI offers the Benevolent Platform™, a next-generation AI platform for life science intelligence. It brings together science and technology teams to push AI and machine learning to new limits, providing life science intelligence at your fingertips.
Who is BenevolentAI for?
BenevolentAI is for scientists, executives, and teams in the biopharma and life sciences industry. Its platform supports them in leveraging cutting-edge AI for their work with confidence and precision.
What is BenevolentAI?
BenevolentAI is an AI drug discovery platform that accelerates biopharma research by applying advanced AI to generate novel insights. It is listed in the Business Specialist category.
5 of 6 research questions are answered for this product. The rest need source evidence we have not collected yet, so they are left unanswered rather than guessed.
Behind the lock
Unlock full BenevolentAI intelligence.
Backlink trajectoryThe figures above are the latest observation. The daily curve behind them holds 370.
AI referral detailHow much traffic assistants send, which one of them does it, and the page they land on.
Search structure and ranking depthOrganic against paid, brand against non-brand, and how many keywords rank in the top three against the long tail — which is what decides whether the demand is portable or tied to the name.
The rest of the marketPage through every leaderboard 100 rows at a time, put any five products side by side, and query the whole dataset over API / MCP.
Worldwide estimates · Data period 2026-05-01 → 2026-07-31. Figures are measured estimates intended for market research. Signals we have not measured for this domain are omitted, never estimated; a measured zero is still reported as zero. How this was measured